FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. PMID 36001857 · J Clin Oncol · 2022-Oct-10 The report is a pooled analysis of two randomized trials (STOMP and ORIOLE) in oligometastatic prostate cancer, which is oncology and human, with a primary time-to-event endpoint (PFS). However, the intervention is metastasis-directed therapy (MDT), which is a non-drug intervention (radiation/surgery), not a drug-containing intervention as required. The trials are not identified as Phase III/IIIb or Phase II/III; the abstract does not specify the phase. The report is a pooled secondary analysis, not the primary result of a single trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial. PMID 36209235 · Trials · 2022-Oct-08 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Meal replacement as a weight loss strategy for night shift workers with obesity: a protocol for a randomized controlled trial. PMID 36209132 · Trials · 2022-Oct-08 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Bilateral verses bilateral with tri-segmental endoscopic drainage using metal stents for high-grade malignant hilar biliary obstructions: A multicenter, randomized controlled trial: BRAVE study (BRAVE study). PMID 36221399 · Medicine (Baltimore) · 2022-Oct-07 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020). PMID 36207035 · BMJ Open · 2022-Oct-07 This record is a retrospective cross-sectional study analyzing accrual rates across multiple oncology trials. It is not an original formal result report of a single randomized trial with a drug intervention and a time-to-event efficacy endpoint. It does not present efficacy results (OS, PFS, etc.) or Kaplan-Meier curves for a specific drug. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A multi-omics-based investigation of the prognostic and immunological impact of necroptosis-related mRNA in patients with cervical squamous carcinoma and adenocarcinoma. PMID 36202899 · Sci Rep · 2022-Oct-06 This is a prognostic/biomarker study analyzing necroptosis-related mRNA in cervical cancer patients using public datasets (TCGA, GEO). It is not a report of a randomized clinical trial with a drug intervention and a time-to-event efficacy endpoint. The publication_type 'Randomized Controlled Trial' appears to be a metadata error, as the abstract describes a bioinformatics analysis, not a trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Complete mesocolic excision in comparison with conventional surgery for right colon cancer: a nationwide multicenter study of the Italian Society of Surgical Oncology colorectal cancer network (CoME-in trial). Study protocol for a randomized controlled trial. PMID 35849819 · Jpn J Clin Oncol · 2022-Oct-06 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting. PMID 35818122 · J Natl Cancer Inst · 2022-Oct-06 The study is a randomized trial in a lung cancer screening population, but the intervention is behavioral counseling with nicotine patches (a smoking cessation aid), not a drug-containing oncology intervention. The primary endpoint is 7-day smoking abstinence (a binary outcome), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the criteria for inclusion in the KM digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031). PMID 35750038 · Jpn J Clin Oncol · 2022-Oct-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The Copenhagen Actinic Keratosis Study (COAKS). A decentralised clinical trial to evaluate tolerability, safety and efficacy of daily field-directed topical treatment with cytosolic phospholipase A2 inhibitor, AVX001, in participants with actinic keratosis: protocol for a randomised controlled phase I/IIa trial. PMID 36198452 · BMJ Open · 2022-Oct-05 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. PMID 35758895 · Cancer Discov · 2022-Oct-05 The record describes a biomarker/prognostic analysis of the placebo-only arm from a randomized trial. While the trial itself may be Phase III, the report does not present results of a drug-containing intervention arm. Therefore, it does not meet the requirement for a drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer. PMID 35679021 · Clin Cancer Res · 2022-Oct-03 The record describes an original FDA approval summary of the COSMIC-311 trial, which is a randomized, double-blind, placebo-controlled Phase III study evaluating cabozantinib in differentiated thyroid cancer. The primary efficacy endpoint is PFS, a time-to-event endpoint, with explicit Kaplan-Meier median estimates and hazard ratio reported. All eligibility criteria are explicitly established in the abstract. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Cytokine-Induced Killer Cell Immunotherapy Combined With Gemcitabine Reduces Systemic Metastasis in Pancreatic Cancer: An Analysis Using Preclinical Adjuvant Therapy-Mimicking Pancreatic Cancer Xenograft Model. PMID 37078953 · Pancreas · 2022-Oct-01 The study is a preclinical, animal-only (murine) investigation of CIK cell therapy combined with gemcitabine. It is not a human clinical trial, does not report Phase III or Phase II/III evidence, and thus does not meet the core eligibility criteria for inclusion in the oncology KM digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Triplet (FOLFOXIRI) Versus Doublet (FOLFOX or FOLFIRI) Regimen as First Line Treatment in Metastatic Colorectal Carcinoma, a Prospective Phase II, Randomized Controlled Trial. PMID 36308367 · Asian Pac J Cancer Prev · 2022-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Circulating Bile Acids and Adenoma Recurrence in the Context of Adherence to a High-Fiber, High-Fruit and Vegetable, and Low-Fat Dietary Intervention. PMID 36113023 · Clin Transl Gastroenterol · 2022-Oct-01 The record is a randomized trial in oncology (colorectal adenoma recurrence) but does not meet all eligibility criteria: it lacks a drug-containing intervention (dietary intervention only), does not report a time-to-event efficacy endpoint (outcome is adenoma recurrence via logistic regression), and the trial phase is not specified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Five-Year Prognosis of Complete Mesocolic Excision in Patients with Colon Cancer: A Prospective, Nonrandomized, Double-Blind Controlled Trial. PMID 36106868 · J Am Coll Surg · 2022-Oct-01 Study is a prospective, nonrandomized, double-blind controlled trial comparing surgical techniques (CME vs. NCME) in colon cancer. It does not involve a drug-containing intervention and is not a Phase III/IIIb or Phase II/III randomized trial of a drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. PMID 36099927 · Lancet · 2022-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. PMID 36048457 · JAMA Oncol · 2022-Oct-01 The record describes a randomized, placebo-controlled, double-blind Phase III clinical trial (CANTATA) with a drug-containing intervention (telaglenastat plus cabozantinib) and a primary time-to-event efficacy endpoint (progression-free survival) with hazard ratio and confidence interval reported. All required criteria are explicitly established. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Sex Differences in Atrial Fibrillation Risk: The VITAL Rhythm Study. PMID 36044209 · JAMA Cardiol · 2022-Oct-01 The study is a randomized trial but examines sex differences in atrial fibrillation risk, which is a non-oncology condition. It investigates the effect of vitamin D and omega-3 supplementation (a drug-containing intervention) but the primary outcome is incident atrial fibrillation, not a cancer-related time-to-event efficacy endpoint. Therefore, it does not meet the oncology eligibility criteria for this cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of Gum Chewing on Recovery From Postoperative Ileus: A Randomized Clinical Trail. PMID 35951432 · J Nurs Res · 2022-Oct-01 The study is a randomized trial in colorectal cancer patients, but it evaluates a non-drug intervention (gum chewing) for postoperative ileus, not a drug for cancer treatment. The endpoint is time to first flatus/defecation, which is a functional recovery measure, not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) for a drug. No drug intervention is present, and no time-to-event survival analysis is reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01. PMID 35895381 · Cancer · 2022-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: 5-Year Outcomes of the KLASS-02 Randomized Clinical Trial. PMID 35857305 · JAMA Surg · 2022-Oct-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease. PMID 35697040 · J Clin Rheumatol · 2022-Oct-01 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
B
|
仅广召回影子组 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. PMID 35658479 · J Clin Oncol · 2022-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Randomized Trial of PHOTOdynamic Surgery in Non-Muscle-Invasive Bladder Cancer. PMID 38319866 · NEJM Evid · 2022-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. PMID 38319837 · NEJM Evid · 2022-Oct The study is a randomized trial of hypomethylating agents for lower-risk Myelodysplastic Syndromes (MDS). While MDS is a hematologic neoplasm with malignant potential, it is not definitively classified as a 'malignant-neoplasm' (e.g., solid tumor or overt leukemia) under strict oncology cohort criteria. Furthermore, the specific trial phase (e.g., Phase II/III or III) is not explicitly confirmed in the abstract or metadata, which is a required criterion for eligibility. Therefore, the record is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of single-dose methotrexate injection to prevent neoplastic changes in high risk complete hydatidiform mole: A randomised control trial. PMID 36618146 · J Family Med Prim Care · 2022-Oct The record is an original, randomized trial in human oncology with a drug intervention and time-to-event endpoint, but the provided metadata does not establish that it is a Phase III/IIIb or Phase II/III trial (required for eligibility). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| How a Digital Case Management Platform Affects Community-Based Palliative Care of Sub-Saharan African Cancer Patients: Clinician-Users' Perspectives. PMID 36384234 · Appl Clin Inform · 2022-Oct Study is an oncology RCT in humans with original results, but it evaluates a digital health intervention (mPCL) for palliative care, not a drug-containing intervention, and does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. PMID 36382554 · Future Oncol · 2022-Oct The record is a clinical trial protocol (ClinicalTrials.gov identifier provided) and not an original formal-result report of a completed trial. The abstract describes a planned study without reporting results, and the phase is not explicitly stated as III/IIIb or II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study. PMID 36306283 · PLoS Med · 2022-Oct The study is a randomized, human, oncology trial analyzing cervical cancer risk, but it is a screening/diagnostic strategy trial (HPV testing and cytology), not a drug intervention trial. The inclusion criteria require a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer. PMID 36267895 · ERJ Open Res · 2022-Oct The record describes a randomized trial of a drug-containing intervention for EGFR-mutated NSCLC with PFS as the primary endpoint and reports HRs, but the abstract and metadata do not explicitly state the trial phase (Phase III/IIIb or Phase II/III). Without clear evidence of being a Phase III/IIIb or Phase II/III trial, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| TC-325 hemostatic powder in the management of upper gastrointestinal malignant bleeding: a randomized controlled trial. PMID 36262517 · Endosc Int Open · 2022-Oct This is a randomized controlled trial in human oncology patients with upper GI malignant bleeding. It is not a Phase III or Phase II/III trial (phase not specified). The primary endpoint is 30-day mortality (a fixed time-point outcome), not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP, and the analysis does not use Kaplan-Meier or report a hazard ratio for such an endpoint. The intervention TC-325 is a hemostatic powder, not a systemic drug therapy for cancer. The study is eligible for inclusion only if it meets all required criteria; here, it fails on phase, drug intervention, and time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A pilot randomized controlled trial on the utility of gastric conditioning in the prevention of esophagogastric anastomotic leak after Ivor Lewis esophagectomy. The APIL_2013 Trial. PMID 36116675 · Int J Surg · 2022-Oct 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. PMID 36113531 · Lancet Glob Health · 2022-Oct The trial is a Phase 3 randomized oncology-related trial with a drug intervention, but it does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier analysis or hazard ratios. The primary endpoint is immunogenicity (seropositivity at 24 months), which is not a time-to-event outcome. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. PMID 36113498 · Lancet Oncol · 2022-Oct The record describes a Phase 3 randomized trial in oncology with primary results, but it is ineligible because it does not meet two core criteria: 1) There is no drug-containing intervention; the interventions are radiotherapy regimens (conventional fractionation vs. SBRT), and androgen deprivation was explicitly not permitted. 2) The primary outcomes are toxicity rates (grade ≥2 gastrointestinal and genitourinary toxicity at 24 months), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. PMID 36097216 · Nat Med · 2022-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Commentary on "Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial". PMID 36096750 · Chin Clin Oncol · 2022-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| [Radiation dose intensification for glioblastoma]. PMID 36085279 · Cancer Radiother · 2022-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Community health workers and precision medicine: A randomized controlled trial. PMID 36084898 · Contemp Clin Trials · 2022-Oct The record describes a randomized controlled trial protocol evaluating a community health worker intervention for precision medicine knowledge. It is not a report of original results from a Phase II/III or III/IIIb drug trial. The primary outcome is knowledge (survey-based), not a time-to-event efficacy endpoint. No drug intervention is specified; the intervention is education and resource connection. The phase is not established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer. PMID 36084395 · ESMO Open · 2022-Oct 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
B
|
仅广召回影子组 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Duct-to-duct biliary reconstruction with or without an intraductal removable stent in liver transplantation: The BILIDRAIN-T multicentric randomised trial. PMID 36082313 · JHEP Rep · 2022-Oct 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Genomics to select treatment for patients with metastatic breast cancer. PMID 36071165 · Nature · 2022-Oct The record describes a randomized trial reporting PFS/HR results for a drug intervention in oncology, but the specific Phase III/IIIb or Phase II/III designation of the randomized trials (NCT02299999 and NCT03386162) is not explicitly provided in the title, abstract, or metadata. The deterministic review flagged unclear phase evidence. Without explicit phase information, eligibility cannot be confirmed. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features. PMID 36057930 · Radiol Med · 2022-Oct The record is a retrospective, model-development study (radiomics nomogram) using data from a cohort of patients treated with imatinib. While it mentions 'Randomized Controlled Trial' as a publication type, this likely refers to the source of the patient data, not the study design itself. The abstract describes a retrospective analysis for predictive modeling, not the primary report of a randomized trial's efficacy results. Therefore, it does not meet the inclusion criteria for an original formal-result report of a randomized trial with a drug intervention and a primary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The impact of driving time on participation in colorectal cancer screening with sigmoidoscopy and faecal immunochemical blood test. PMID 36057171 · Cancer Epidemiol · 2022-Oct The record describes a randomized trial on colorectal cancer screening participation, which is oncology-related and human. However, it lacks several key eligibility criteria: it is not specified as a Phase III/IIIb or Phase II/III drug trial; the intervention is non-drug (sigmoidoscopy and faecal immunochemical test); and the primary endpoint is participation rate (a process measure), not a time-to-event efficacy endpoint like OS or PFS. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101. PMID 36037566 · ESMO Open · 2022-Oct The abstract presents a secondary/subgroup analysis of the phase III JAVELIN Renal 101 trial, focusing on the predictive value of CRP levels for efficacy. It is not a primary or key secondary report of the overall trial's efficacy results. The required criterion for a primary/key secondary time-to-event efficacy endpoint for the overall trial population is not met, as the focus is on a biomarker-defined subgroup. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer. PMID 36029653 · ESMO Open · 2022-Oct The trial is randomized, oncology, human, drug-intervention, and reports time-to-event efficacy (PFS, OS) with HRs, but the metadata does not confirm it is a Phase III/IIIb or Phase II/III trial. The abstract describes it as 'signal-seeking' and 'adaptable', which may indicate earlier-phase or exploratory design. Phase evidence is unclear from the provided information. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis. PMID 36007449 · ESMO Open · 2022-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Evaluating a game-based randomized experiment to increase melanoma identification among adults living in the U.S. PMID 36001916 · Soc Sci Med · 2022-Oct The study is a randomized controlled trial in melanoma detection, but it evaluates behavioral training strategies (ABCD, Ugly Duckling) and feedback, not a drug-containing intervention. It also lacks any time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the core eligibility criteria for drug-based, time-to-event oncology trials. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial. PMID 35999259 · Leukemia · 2022-Oct The study is a biomarker sub-analysis from a phase IIIb trial, not an original report of a primary or key secondary time-to-event efficacy endpoint for the drug intervention in the randomized trial context. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Development and validation of a prognostic gene expression signature for lower-grade glioma following surgery and adjuvant radiotherapy. PMID 35998839 · Radiother Oncol · 2022-Oct The record describes a prognostic gene expression signature study, not a drug efficacy trial. While it involves human oncology, time-to-event endpoints, and randomized cohort assignment for validation, it lacks a Phase III/IIIb or Phase II/III randomized drug intervention trial design. The 'drug intervention' criterion is not met as the study is not primarily evaluating a drug within a randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |